NCT05684744View on ClinicalTrials.gov

Roflumilast Versus Methotrexate in Psoriasis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

May 9, 2023

Study Completion Date

May 14, 2023

Conditions
Psoriasis
Interventions
DRUG

Roflumilast

The patients will receive oral roflumilast in a dose of 500 mcg per day for 12 weeks

DRUG

Methotrexate

The patients will receive methotrexate in a dose of 0.2- 0.4 mg/kg/week for 12 weeks

Trial Locations (1)

Unknown

Cairo University, Cairo

All Listed Sponsors
lead

Cairo University

OTHER